Pacifico Biolabs raises €7M to turn brewery infrastructure into protein production

PacificoBiolabs, a mycelium fermentation protein company, has raised €7 million in a Series A funding round backed by Stray Dog Capital, TGFS, Sprout & About Ventures, Simon Capital, FoodLabs, and a regional brewery partner.

Pacifico Biolabs develops protein ingredients using mycelium fermentation technology. Instead of relying on purpose-built bioreactors, the company uses standard beer brewery fermentation tanks, enabling it to leverage existing industrial infrastructure while avoiding the high costs typically associated with fermentation-based food production.

The approach comes as breweries across Europe face declining beer and alcohol consumption, leaving fermentation capacity underutilised. Pacifico sees this as an opportunity to scale production more quickly and cost-effectively by repurposing existing brewery infrastructure rather than building new facilities.

At the same time, Europe continues to rely heavily on imported feed protein despite producing most of its own meat, leaving supply chains exposed to environmental and geopolitical risks. Pacifico aims to provide a domestically produced protein alternative manufactured closer to where it is consumed, using regional industrial capacity.

By using existing brewery infrastructure, the company aims to lower production costs and move closer to price parity with conventional meat products.

The funding will support production scaling in Saxony, Germany, team expansion, and commercial launches across the DACH region and Nordic Europe ahead of planned retail launches by late 2026.